U.S., July 8 -- ClinicalTrials.gov registry received information related to the study (NCT07686068) titled 'First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors' on June 30.
Brief Summary: This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.
Study Start Date: Aug. 18
Study Type: INTERVENTIONAL
Condition:
Participants With Advanced Solid Tumor Malignancies
Intervention:
DRUG:...